Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15007 total
Tapestry enters the post-earnings session sharply lower, with a 20% weekly decline having wiped out months of gains following a Q4 print that landed well below the optimism priced in. The selloff is the dominant fact…
Charles River Laboratories heads into the back half of August with a striking divergence: a 21% monthly rally driven by a blowout earnings reaction, yet insider selling accelerating at almost every level of the…
COF heads into the back half of August with a clean bid — up 4.4% on the week and 10.7% over the past month — while shorts are quietly covering and the lending market remains among the loosest in its peer group. The…
BA heads into the back half of August with a sharply upgraded consensus but a stock that has quietly given back ground — a tension worth watching. The Street turned decisively more constructive on Boeing this month.…
Badger Meter heads into the back half of August with short sellers adding positions at their fastest weekly pace in months, even as the stock stabilises near a multi-month low after a brutal earnings reaction. The…
AMETEK arrives at mid-August in a quietly constructive position — a stock that just posted a well-received quarter, collected a round of analyst target upgrades, and continues to attract almost no meaningful bearish…
American Electric Power enters the back half of August with a notable disconnect: its closest utility peers are broadly higher on the week while AEP has slipped, and the options market just flashed one of its most…
Allstate has seen its most dramatic short-interest unwind of the year in the nine days since Q2 results landed — but the analyst community that consensus note flagged as divided has only grown more fractured since. The…
Akamai Technologies has staged a sharp recovery from its post-earnings lows, yet the short interest and options data tell a more complicated story beneath the surface. The most decisive development this week came from…
CoreCivic enters the week after its Q2 print in a dramatically different positioning landscape — short interest has exploded, insiders are selling aggressively, and the borrow market has tightened sharply from the…
Ironwood Pharmaceuticals heads into the back half of August with a notable divergence at its core — short sellers are unwinding positions even as the stock trades at a fraction of where analysts think it should be. The…
BA has entered a quieter phase after weeks of sharp analyst upgrades and short covering activity, and the question now is whether the fundamental story is strong enough to drive the next leg without those…
RDDT heads into the week of August 14 with a notable tension: short interest has climbed meaningfully since late July even as the stock bounced hard off its post-earnings lows, setting up a tug-of-war between…
PINS has handed back most of its post-earnings pop, sliding back to $23.32 after touching $25.58 the week of results — and the most consistent sellers in recent weeks have been the people who built the company. The…
ERIC enters the autumn earnings cycle carrying the weight of a brutal July report — and with the next results date just two months out, the question is whether the stock's modest recovery is building on solid ground or…
AST SpaceMobile has delivered its most significant change in short positioning in months, with bears covering at scale following the August 10 earnings release — yet the stock, at $71.52, is still down 3.8% from its…
SMR enters the week carrying real momentum, up 6.7% over the past five sessions and 2.8% on Thursday alone, yet that rally sits against a backdrop of sharply divergent peer performance and a fresh earnings scar that is…
Latitude Group Holdings enters its August 21 results with a lending market that tells a more interesting story than the flat price action suggests. The standout this week is cost to borrow. Borrow costs have jumped to…
Visa is in a holding pattern — the post-earnings momentum has faded, the stock has given back a little more ground, and the next hard catalyst is still ten weeks away. The price action this week tells a steady,…
Iovance Biotherapeutics enters the new week in a genuinely unusual position — a stock up 55% in five days that still carries one of the heaviest short books in biotech, with options traders now at their most defensive…
